Fed Circuit sides with Gilead over hep C patent

The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

MSD petitions SCOTUS over $2.5bn patent verdict

28 September 2020 MSD subsidiary Idenix has urged the US Supreme Court to review the overturning of a record $2.5 billion verdict against Gilead Sciences.

Big Pharma

Brazil accuses Gilead over 1,421.5% price hike of hep C drug

24 October 2019 The Brazilian Federal Public Defender’s Office has filed a complaint against Gilead for hugely increasing the price of its hepatitis C drug since it gained patent protection.

Big Pharma

Fed Circuit sides with Merck in antifungal treatment dispute

25 June 2019 A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.

More features

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation: Follow the money (Part I)

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

Fed Circuit sides with Gilead over hep C patent

More on this story

Editor's picks

Editor's picks

More features